The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study

• Главные авторы: Jatinder K. Mukker (Автор), George Dukes (Автор), Max Tolkoff (Автор), Lisi Wang (Автор), Cristina Almansa (Автор), Susanna Y. Huh (Автор), Mitsuhiro Nishihara (Автор), Diane Ramsden (Автор), Chunlin Chen (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2022-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Trazpiroben is a dopamine D2/D3 receptor antagonist under development for the treatment of gastroparesis. This phase I, open‐label, randomized, two‐way crossover study (NCT04121078) evaluated the effect of single‐dose intravenous rifampin, a potent inhibitor of the organic anion transportin...